News For Gilead Sciences


This RSS feed URL is deprecated

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Google 9/25/2018 8:34:39 PM

Gilead to launch generic versions of its hepatitis drugs - Reuters


Reuters

Gilead to launch generic versions of its hepatitis drugs
Reuters
Gilead said the low-cost variants of the drugs will be available at a list price of $24,000 for the most common course of therapy from January. U.S. healthcare companies, ranging from insurers to drug retailers, are stepping up efforts to combat rising ...
Gilead to Sell Cheaper Versions of Drug That Sparked Cost DebateBloomberg
Gilead to Slice List Prices of Liver Drugs - WSJWall Street Journal
Gilead to offer cheaper version of its $1000 a pill hepatitis drugsBusiness Insider
Pharmacy Times -StreetInsider.com -Express Scripts
all 61 news articles »
Google 9/24/2018 8:51:00 PM

Brazil court strips Gilead of hepatitis C drug patent | Reuters - Reuters


Reuters

Brazil court strips Gilead of hepatitis C drug patent | Reuters
Reuters
BRASILIA/SAO PAULO (Reuters) - A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the ...
Brazil court strips Gilead of hepatitis C drug patentWHBL News
Brazil court strips Gilead hepatitis drug patent, politician saysFiji Times

all 28 news articles »
Google 9/24/2018 8:27:30 PM

Gilead to launch generic versions of Epclusa and Harvoni - Seeking Alpha


Gilead to launch generic versions of Epclusa and Harvoni
Seeking Alpha
Gilead Sciences (NASDAQ:GILD) announces that newly created subsidiary Asegua Therapeutics LLC will launch authorized generic versions of hepatitis C meds Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the U.S.. The drugs ...

Google 9/24/2018 12:42:00 PM

What's Next For Gilead? - Seeking Alpha


What's Next For Gilead?
Seeking Alpha
Gilead (GILD) reported better than expected Q2 results and has been making progress with its pipeline over the last couple of months. It looks like 2018 could be the bottom, and revenues might increase again next year. This, coupled with a promising ...

Google 9/21/2018 12:33:47 PM

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance


Yahoo Finance

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Yahoo Finance
Gilead Sciences (GILD) closed at $73.88 in the latest trading session, marking a +0.31% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow added 0.61%, and the tech-heavy Nasdaq lost 0.08%.

and more »
Google 9/19/2018 9:45:00 PM

Gilead Faces Doubts on Wall Street a Year After $12 Billion Deal - Bloomberg


Bloomberg

Gilead Faces Doubts on Wall Street a Year After $12 Billion Deal
Bloomberg
Sales of Kite's first treatment, Yescarta, failed to impress in its first two full quarters on the market and competition is looming. Adding to concerns, Gilead's long-time chairman, chief executive officer and chief medical officer have all recently ...

and more »
Google 9/19/2018 6:36:59 PM

Gilead: Forming A Base? - Seeking Alpha


Zacks.com

Gilead: Forming A Base?
Seeking Alpha
Biotech stocks have surged this year, soundly outperforming the S&P 500. Gilead Sciences should benefit from these trends and may be forming a base in its latest moves higher. Sequential revenue gains and rising EPS guidance factors suggest Gilead's ...
Is Gilead (GILD) a Suitable Stock for Value Investors Now?Zacks.com
There's Some Concern Under The Hood: Gilead Sciences, Inc. (GILD)NMSU Nеws
Notable Intraday Movers: Gilead Sciences, Inc., (NASDAQ: GILD), ServiceNow, Inc., (NYSE: NOW)Global Export Lines (press release)
Fairfield Current -Nyse Trading News (press release) -StockNewsGazette -Zacks
all 201 news articles »
Google 9/18/2018 1:35:00 PM

 1 2